Combinatorial library strategies for synthesis of cationic lipid-like nanoparticles and their potential medical applications

Nanomedicine

Volumn 10, Issue 4, 2015, Pages 643-657

  Altinoglu, Sarah ^a   Wang, Ming ^a   Xu, Qiaobing ^a  

^a Tufts University   (United States)

Author keywords

combinatorial; gene delivery; high throughput screening; lipidoid; protein delivery

Indexed keywords

ACRYLAMIDE DERIVATIVE; ACRYLIC ACID DERIVATIVE; AMINE; CATIONIC LIPID LIKE NANOPARTICLE; EPOXIDE; NANOPARTICLE; UNCLASSIFIED DRUG; CATION; LIPID;

ALKYLATION; CHEMICAL STRUCTURE; CLICK CHEMISTRY; COMBINATORIAL LIBRARY; DRUG DELIVERY SYSTEM; HIGH THROUGHPUT SCREENING; HUMAN; MICHAEL ADDITION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOLID PHASE SYNTHESIS; ANIMAL; CHEMISTRY; COMBINATORIAL CHEMISTRY; GENE TRANSFER; PROCEDURES; SYNTHESIS;

ANIMALS; CATIONS; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DELIVERY SYSTEMS; GENE TRANSFER TECHNIQUES; HUMANS; LIPIDS; NANOPARTICLES;

EID: 84924190196     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.14.192     Document Type: Review

References (69)

1. Kostarelos K, Miller AD. What role can chemistry play in cationic liposome-based gene therapy research today? In: Non-Viral Vectors for Gene Therapy: Part 1 (2nd Edition), 71-118 (2005).
2. Namiki Y, Fuchigami T, Tada N et al. Nanomedicine for cancer: lipid-based nanostructures for drug delivery and monitoring. Acc. Chem. Res. 44(10), 1080-1093 (2011).
3. Donkuru M, Badea I, Wet tig S, Verrall R, Elsabahy M, Foldvari M. Advancing nonviral gene delivery: lipid-and surfactant-based nanoparticle design strategies. Nanomedicine 5(7), 1103-1127 (2010).
4. Lin Q, Chen J, Zhang Z, Zheng G. Lipid-based nanoparticles in the systemic delivery of siRNA. Nanomedicine 9(1), 105-120 (2014).
5. Zhang S, Zhi D, Huang L. Lipid-based vectors for siRNA delivery. J. Drug Target. 20(9), 724-735 (2012).
6. Li W, Szoka FC Jr. Lipid-based nanoparticles for nucleic acid delivery. Pharmaceut. Res. 24(3), 438-449 (2007).
7. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev. 65(1), 36-48 (2013).
8. Schroeder A, Levins CG, Cortez C, Langer R, Anderson DG. Lipid-based nanotherapeutics for siRNA delivery J. Intern. Med. 267(1), 9-21 (2010).
9. Felgner PL, Ringold GM. Cationic liposome-mediated transfection. Nature 337(6205), 387-388 (1989).
10. Malone RW, Felgner PL, Verma IM. Cationic liposome-mediated RNA transfection. Proc. Natl Acad. Sci. USA 86(16), 6077-6081 (1989).
11. Pierrat P, Creusat G, Laverny G, Pons F, Zuber G, Lebeau L. A cationic phospholipid-detergent conjugate as a new effcient carrier for siRNA delivery Chem. Eur. J. 18(13), 3835-3839 (2012).
12. Zhao Y-N, Qureshi F, Zhang S-B et al. Novel Gemini cationic lipids with carbamate groups for gene delivery J. Mater. Chem. B 2(19), 2920-2928 (2014).
13. Akinc A, Zumbuehl A, Goldberg M et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat. Biotech. 26(5), 561-569 (2008).
14. De Lima MCP, Simoes S, Pires P, Faneca H, Duzgunes N. Cationic lipid-DNA complexes in gene delivery: from biophysics to biological applications. Adv. Drug Deliv. Rev. 47(2-3), 277-294 (2001).
15. Lazo JS, Wipf P. Combinatorial chemistry and contemporary pharmacology. J. Pharm. Exp. Ther. 293(3), 705-709 (2000).
16. Whitehead KA, Matthews J, Chang PH et al. In vitro-in vivo translation of lipid nanoparticles for hepatocellular siRNA delivery. ACS Nano 6(8), 6922-6929 (2012).
17. Whitehead KA, Dorkin JR, Vegas AJ et al. Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity. Nat. Commun. 5, 4277 (2014).
18. Mahon KP, Love KT, Whitehead KA et al. Combinatorial approach to determine functional group effects on lipidoid-mediated siRNA delivery. Bioconj. Chem. 21(8), 1448-1454 (2010).
19. Love KT, Mahon KP, Levins CG et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc. Natl Acad. Sci. USA 107(5), 1864-1869 (2010).
20. Akinc A, Goldberg M, Qin J et al. Development of lipidoid-siRNA formulations for systemic delivery to the liver. Mol. Ther. 17(5), 872-879 (2009).
21. Wang M, Alberti K, Varone A, Pouli D, Georgakoudi I, Xu Q. Enhanced intracellular siRNA delivery using bioreducible lipid-like nanoparticles. Adv. Healthcare Mater. 3(9), 1398-1403 (2014).
22. Sun S, Wang M, Knupp SA et al. Combinatorial library of lipidoids for in vitro DNA delivery. Bioconj. Chem. 23(1), 135-140 (2012).
23. Wang M, Sun S, Alberti KA, Xu Q. A combinatorial library of unsaturated lipidoids for effcient intracellular gene delivery ACS Synth. Biol. 1(9), 403-407 (2012).
24. Xue W, Dahlman Je, Tammela T et al. Small RNA combination therapy for lung cancer. Proc. Natl Acad. Sci. USA 111(34), E3553-E3561 (2014).
25. Lenssen K, Jantscheff P, Von Kiedrowski G, Massing U. Combinatorial synthesis of new cationic lipids and high-throughput screening of their transfection properties. Chem Bio Chem 3(9), 852-858 (2002).
26. Goldberg M. Lipidoids: a combinatorial approach to siRNA delivery. In: RNA Interference from Biology to Therapeutics. Howard KA (Ed.). Springer, NY, USA, 143-160 (2013).
27. Behr JP, Demeneix B, Loeffer JP, Mutul JP. Effcient gene-transfer into mammalian primary endocrine-cells with lipopolyamine-coated DNA. Proc. Natl Acad. Sci. USA 86(18), 6982-6986 (1989).
28. Shirazi RS, Ewert KK, Leal C, Majzoub RN, Bouxsein NF, Safnya CR. Synthesis and characterization of degradable multivalent cationic lipids with disulfde-bond spacers for gene delivery Biochim. Biophys. Acta Biomemb. Biomembranes 1808(9), 2156-2166 (2011).
29. Merrifeld B. Concept and early development of solid-phase peptide synthesis. In: Methods in Enzymology. Gregg BF (Ed.). Academic Press, NY, USA, 3-13 (1997).
30. Yingyongnarongkul B-E, Howarth M, Elliott T, Bradley M. Solid-phase synthesis of 89 polyamine-based cationic lipids for DNA delivery to mammalian cells. Chem. Eur. J. 10(2), 463-473 (2004).
31. Radchatawedchakoon W, Watanapokasin R, Krajarng A, Yingyongnarongkul B-E. Solid phase synthesis of novel asymmetric hydrophilic head cholesterol-based cationic lipids with potential DNA delivery. Bioorg. Med. Chem. 18(1), 330-342 (2010).
32. Liberska A, Lilienkampf A, Unciti-Broceta A, Bradley M. Solid-phase synthesis of arginine-based double-tailed cationic lipopeptides: potent nucleic acid carriers. Chem. Commun. 47(48), 12774-12776 (2011).
33. Nair DP, Podgórski M, Chatani S et al. The thiol-michael addition click reaction: a powerful and widely used tool in materials chemistry. Chem. Mater. 26(1), 724-744 (2013).
34. Nguyen DN, Mahon KP, Chikh G et al. Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery. Proc. Natl Acad. Sci. USA 109(14), E797-E803 (2012).
35. Cho SW, Goldberg M, Son SM et al. Lipid-like nanoparticles for small interfering RNA delivery to endothelial cells. Adv. Funct. Mater. 19(19), 3112-3118 (2009).
36. Wang M, Alberti K, Sun S, Arellano Cl, Xu QB. Combinatorially designed lipid-like nanoparticles for intracellular delivery of cytotoxic protein for cancer therapy. Angew. Chem. Int. Ed. 53(11), 2893-2898 (2014).
37. Dong Y, Eltoukhy AA, Alabi Ca et al. Lipid-like nanomaterials for simultaneous gene expression and silencing in vivo. Adv. Healthc. Mater. 3(9), 1392-1397 (2014).
38. Kolb HC, Finn MG, Sharpless KB. Click chemistry: diverse chemical function from a few good reactions. Angew. Chem. Int. Ed. 40(11), 2004-2021 (2001).
39. Li LX, Zahner D, Su Y, Gruen C, Davidson G, Levkin PA. A biomimetic lipid library for gene delivery through thiol-yne click chemistry. Biomaterials 33 (32), 8160-8166 (2012).
40. Alabi CA, Love KT, Sahay G et al. Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery Proc. Natl Acad. Sci. USA 110(32), 12881-12886 (2013).
41. Sheng RL, Luo T, Li H, Sun JJ, Wang Z, Cao A. 'Click' synthesized sterol-based cationic lipids as gene carriers, and the effect of skeletons and headgroups on gene delivery Bioorg Med. Chem. 21(21), 6366-6377 (2013).
42. Li LX, Wang FJ, Wu YH, Davidson G, Levkin PA. Combinatorial synthesis and high-throughput screening of alkyl amines for conviral gene delivery. Bioconj. Chem. 24(9), 1543-1551 (2013).
43. Salvatore RN, Nagle AS, Jung KW. Cesium effect: high chemoselectivity in direct N-alkylation of amines. J. Org Chem. 67(3), 674-683 (2002).
44. Felgner JH, Kumar R, Sridhar CN et al. Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J. Biol. Chem. 269(4), 2550-2561 (1994).
45. Suma T, Miyata K, Anraku Y et al. Smart multilayered assembly for biocompatible siRNA delivery featuring dissolvable silica, endosome-disrupting polycation, and detachable PEG. ACS Nano 6(8), 6693-6705 (2012).
46. Gehin C, Montenegro J, Bang E-K et al. Dynamic amphiphile libraries to screen for the "fragrant" delivery of siRNA into HeLa cells and human primary fbroblasts. J. Am. Chem. Soc. 135(25), 9295-9298 (2013).
47. Candiani G, Pezzoli D, Ciani L, Chiesa R, Ristori S. Bioreducible liposomes for gene delivery: from the formulation to the mechanism of action. PLoS ONE 5(10), e13430 (2010).
48. Saito G, Swanson JA, Lee K-D. Drug delivery strategy utilizing conjugation via reversible disulfde linkages: role and site of cellular reducing activities. Adv. Drug Deliv. Rev. 55(2), 199-215 (2003).
49. Whitehead KA, Sahay G, Li GZ et al. Synergistic silencing: combinations of lipid-like materials for effcacious siRNA delivery. Mol. Ther. 19(9), 1688-1694 (2011).
50. Sun S, Wang M, Alberti KA, Choy A, Xu Q. DOPE facilitates quaternized lipidoids (QLDs) for in vitro DNA delivery. Nanomedicine 9(7), 849-854 (2013).
51. Karmali PP, Chaudhuri A. Cationic liposomes as non-viral carriers of gene medicines: resolved issues, open questions, and future promises. Med. Res. Rev. 27(5), 696-722 (2007).
52. Wheeler JJ, Palmer L, Ossanlou M et al. Stabilized plasmid-lipid particles: construction and characterization. Gene Ther. 6(2), 271-281 (1999).
53. Shim G, Kim M-G, Park JY, Oh Y-K. Application of cationic liposomes for delivery of nucleic acids. Asian J. Pharm. Sci. 8(2), 72-80 (2013).
54. Röther S, Meister G. Small RNAs derived from longer non-coding RNAs. Biochimie 93(11), 1905-1915 (2011).
55. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 8(2), 129-138 (2009).
56. Ku SH, Kim K, Choi K, Kim SH, Kwon IC. Tumor-targeting multifunctional nanoparticles for siRNA delivery: recent advances in cancer therapy. Adv. Healthc. Mater. 3(8), 1182-1193 (2014).
57. Williford J-M, Wu J, Ren Y, Archang MM, Leong KW, Mao H-Q. Recent advances in nanoparticle-mediated siRNA delivery. Annu. Rev. Biomed. Eng. 16(1), 347-370 (2014).
58. Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG. Non-viral vectors for gene-based therapy. Nat. Rev. Genet. 15(8), 541-555 (2014).
59. Zhang S, Zhao Y, Zhi D, Zhang S. Non-viral vectors for the mediation of RNAi. Bioorg. Chem. 40(0), 10-18 (2012).
60. Shu Y, Pi F, Sharma A et al. Stable RNA nanoparticles as potential new generation drugs for cancer therapy. Adv. Drug Deliv. Rev. 66(0), 74-89 (2014).
61. Wasungu L, Hoekstra D. Cationic lipids, lipoplexes and intracellular delivery of genes. J. Control. Release 116(2), 255-264 (2006).
62. Nguyen DN, Chen Scy, Lu J et al. Drug delivery-mediated control of RNA immunostimulation. Mol. Ther. 17(9), 1555-1562 (2009).
63. Scholz C, Wagner E. Therapeutic plasmid DNA versus siRNA delivery: common and different tasks for synthetic carriers. J. Control. Release 161(2), 554-565 (2012).
64. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomed. 1(3), 297-315 (2006).
65. Matthews T, Salgo M, Greenberg M, Chung J, Demasi R, Bolognesi D. Enfuvirtide: the frst therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat. Rev. Drug Discov. 3(3), 215-225 (2004).
66. Vogel CL, Cobleigh MA, Tripathy D et al. Effcacy and safety of trastuzumab as a single agent in frst-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20(3), 719-726 (2002).
67. Silkoff PE, Romero FA, Gupta N, Townley RG, Milgrom H. Exhaled nitric oxide in children with asthma receiving xolair (Omalizumab), a monoclonal anti-immunoglobulin E antibody. Pediatrics 113(4), e308-e312 (2004).
68. Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classifcation. Nat. Rev. Drug Discov. 7(1), 21-39 (2008).
69. Pisal DS, Kosloski M P, Balu-Iyer SV. Delivery of therapeutic proteins. J. Pharm. Sci. 99(6), 2557-2575 (2010).